Improving Patient Adherence and Quality of Life in Prostate Cancer: Strategies for Managing Treatment Related Adverse Events Associated with PARP Inhibitor Regimens

A continuing medical education activity provided by NAMCP and AAMCN

Clinical Advances in the Treatment of Prostate Cancer: A Closer Look at the Role of PARP Inhibitors
is a three-part webinar series

This is Part 3 of the series focusing on patient adherence and quality of life
in the management and treatment of prostate cancer

This activity is an archive from the webinar held February 17, 2021

This activity is valid from March 1, 2021 to March 1, 2023

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

Prostate cancer is the most diagnosed non-cutaneous cancer in men in the US and remains the second leading cause of cancer deaths among American men, with an estimated 174,000 new cases diagnosed in 2020. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. Fortunately for these patients, novel therapies have changed the treatment paradigm, as recent data has shown that newer options, including PARP inhibitors, greatly improves outcomes. outcomes.

Upon completion of this activity, participants will be able to:

  • Examine challenges to patient adherence, administration and quality of life in the management of prostate cancer

  • Discuss strategies to implement PARP inhibitors into the treatment paradigm, especially as it relates to patient adherence and quality of life

  • Define strategies for anticipating, recognizing, and managing adverse events of PARP inhibitor therapy in patients with prostate cancer

  • Explore the role of PARP inhibitors in the management of prostate cancer


Faculty: Neeraj Agarwal, MD
Professor of Medicine
Huntsman Cancer Institute (HCI) Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)


Dr. Agarwal has served as a consultant for Astellas, AstraZeneca, Argos, BMS, Bayer, Clovis, Eisai, Exelixis, EMD Serono, Ely Lilly, Genentech, Merck, Medivation, Novartis, Nektar, Pfizer, Pharmacyclics, and Seattle Genetics. He has received grants/research funding from Active Biotech, Astra Zeneca, Bavarian Nordic, Bayer Oncology, BMS, Calithera, Celldex, Eisai, Exelixis, Genetech, GSK (glaxosmithkline), Immunomedics, Janssen, Medivation, Merck, New link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Sanofi, Takeda, and Tracon. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue